Periphery biomarkers, such as lower levels of cerebrospinal fluid (CSF) Aβ, indicate increased accumulation in the brain, whereas increased CSF tau levels indicate damaged neuronal microtubules, clearly evidencing synaptic dysfunction (i.e., desynchronization and hypersynchronization) due to AD (119) that negatively impacts synaptic plasticity and causes synaptic loss, which in turn leads to impairment of neural networks involved in memory and cognition. The gene discussed is MAPT; the disease is Alzheimer disease.